Tumor Regression After Treatment With Lenvatinib in FGFR2-Mutated Ameloblastoma-Reference-Cited by-同舟云学术

登录注册会员服务联系我们

Tumor Regression After Treatment With Lenvatinib in FGFR2-Mutated Ameloblastoma

Published:2020-11 Issue:4 Volume: Page:1403-1406
ISSN:2473-4284
Container-title:JCO Precision Oncology
language:en
Short-container-title:JCO Precision Oncology

Author:

Weaver Alice N.¹,Francisque Frantz²,Bowles Daniel W.²³

Affiliation:

1. Department of Medicine, Internal Medicine Residency Training Program, University of Alabama at Birmingham, Birmingham, AL

2. Department of Medicine, Division of Medical Oncology, University of Colorado, Aurora, CO

3. Rocky Mountain Regional VA Medical Center, Aurora, CO

Publisher

American Society of Clinical Oncology (ASCO)

Subject

Cancer Research,Oncology

Link

https://ascopubs.org/doi/pdfdirect/10.1200/PO.20.00175

Reference39 articles.

1. FGF Receptors: Cancer Biology and Therapeutics

2. The FGFR Landscape in Cancer: Analysis of 4,853 Tumors by Next-Generation Sequencing

3. Prognostic Impact of Fibroblast Growth Factor 2 in Non-small Cell Lung Cancer: Coexpression with VEGFR-3 and PDGF-B Predicts Poor Survival

4. FGFR1 Amplification Drives Endocrine Therapy Resistance and Is a Therapeutic Target in Breast Cancer

5. A mechanism of resistance to gefitinib mediated by cellular reprogramming and the acquisition of an FGF2-FGFR1 autocrine growth loop

Cited by 8 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Anti-MAPK Targeted Therapy for Ameloblastoma: Case Report with a Systematic Review;Cancers;2024-06-07

2. Targeted therapies in ameloblastomas and amelobastic carcinoma—A systematic review;Oral Diseases;2024-05

3. Molecular pathogenesis of ameloblastoma;Journal of Oral Pathology & Medicine;2024-04-25

4. Solid-Basaloid Adenoid Cystic Carcinoma of the Breast: An Aggressive Subtype Enriched for Notch Pathway and Chromatin Modifier Mutations With MYB Overexpression;Modern Pathology;2023-12

5. Treatment options for advanced ameloblastoma in the era of precision medicine: A brief review;Oral Oncology;2023-11

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线，采集、加工和组织学术论文而形成的新型学术文献查询和分析系统，可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容，当前同舟云学术共收录了国内外主流学术期刊6万余种，收集的期刊论文及会议论文总量共计约1.5亿篇，并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询！咨询电话：010-8811{复制后删除}0370

www.globalauthorid.com

TOP

Copyright © 2019-2024 北京同舟云网络信息技术有限公司
京公网安备11010802033243号京ICP备18003416号-3